

## Pharmacokinetic effects of a single-dose nutritional ketone ester supplement on brain ketone and glucose metabolism in alcohol use disorder – a pilot study

1 Xinyi Li<sup>1</sup>, Anthony J. Young<sup>2</sup>, Lais S. Pereira-Rufino<sup>1</sup>, Zhenhao Shi<sup>1</sup>, Juliana Byanyima<sup>1</sup>,  
2 Siannah Vesslee<sup>1</sup>, Rishika Reddy<sup>1</sup>, Timothy Pond<sup>1</sup>, Mark Elliott<sup>2</sup>, Ravinder Reddy<sup>2</sup>, Robert K.  
3 Doot<sup>2</sup>, Jan-Willem van der Veen<sup>3</sup>, Henry R. Kranzler<sup>1</sup>, Ravi Prakash Reddy Nanga<sup>2</sup>, Jacob G.  
4 Dubroff<sup>2</sup>, Corinde E. Wiers<sup>1</sup>

5 <sup>1</sup>Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine,  
6 Department of Psychiatry, Philadelphia, PA

7 <sup>2</sup>University of Pennsylvania Perelman School of Medicine, Department of Radiology, Philadelphia,  
8 PA

9 <sup>3</sup>National Institute on Mental Health, National Institutes of Health, 10 Center Drive, Bethesda, MD

10 **\* Correspondence:**

11 Corinde E. Wiers, Ph.D.  
12 [corinde.wiers@penmedicine.upenn.edu](mailto:corinde.wiers@penmedicine.upenn.edu)

13

14 **Keywords:** beta-hydroxybutyrate, brain energetics, ketogenic diet, krebs cycle, metabolism,  
15 nutritional supplement

16

## 17 **Abstract**

18 **Introduction:** Acute alcohol intake decreases brain glucose metabolism and increases brain uptake of  
19 acetate, a metabolite of alcohol. Individuals with alcohol use disorder (AUD) show elevated brain  
20 acetate metabolism at the expense of glucose, a shift in energy utilization that persists beyond acute  
21 intoxication. We recently reported that nutritional ketosis and administration of ketone bodies as an  
22 alternative energy source to glucose reduce alcohol withdrawal severity and alcohol craving in AUD.  
23 However, the regional effects of nutritional ketosis on brain ketone (beta-hydroxybutyrate [BHB]) and  
24 glucose metabolism have not been studied in AUD.

25 **Methods:** Five participants with AUD underwent two magnetic resonance imaging (MRI) sessions and  
26 4 participants with AUD underwent two positron emission tomography (PET) sessions with <sup>18</sup>F-  
27 fluorodeoxyglucose. All participants completed one session without KE intervention and one session  
28 during which they consumed 395 mg/kg (*R*)-3-hydroxybutyl (*R*)-3-hydroxybutyrate Ketone Ester (KE)  
29 intervention (TdeltaS Global Inc.) before the scan. The order of the sessions was randomized. For the  
30 PET cohort, blood glucose and ketone levels were assessed and voxel-wise maps of the cerebral  
31 metabolic rate of glucose (CMR<sub>glc</sub>) were computed at each session. For the MRI cohort, brain anterior  
32 cingulate BHB levels were assessed using magnetic resonance spectroscopy.

## 33 **Results**

34 A single dose of KE elevated blood BHB and anterior cingulate BHB levels compared to baseline.  
35 Moreover, blood glucose levels were lower with KE than baseline, and whole-brain CMR<sub>glc</sub> decreased  
36 by 17%. The largest KE-induced CMR<sub>glc</sub> reductions were in the frontal, occipital, cortex, and anterior  
37 cingulate cortices.

## 38 **Conclusion**

39 These findings provide preliminary evidence that KE administration elevates ketone and reduces brain  
40 glucose metabolism in humans, consistent with a shift from glucose to ketones as a brain energy source.  
41 Average reductions in CMR<sub>glc</sub> of 17% are similar to global average reductions documented with  
42 administration of 0.25-0.5 g/kg of alcohol. Documenting the clinical and neurometabolic effects of  
43 nutritional ketosis will yield fundamental knowledge as to its potential beneficial effects as a treatment  
44 for AUD and its underlying neural mechanisms.

45

## 46 1 Introduction

47 Alcohol use disorder (AUD) is a chronic, relapsing condition that is associated with substantially  
48 elevated risk of neurocognitive impairments, co-occurring medical and psychiatric disorders, and  
49 mortality. In the United States, approximately 95,000 alcohol-related deaths were reported annually  
50 between 2011 and 2015, making alcohol the third-leading cause of preventable death (Esser et al.  
51 2020). However, only 1.6 % of patients with AUD receive FDA-approved medications to treat the  
52 disorder (Han et al. 2021) and available treatments are not efficacious for all patients (Campbell et al.  
53 2018).

54 Improving brain energetics in individuals with AUD is a novel potential therapeutic intervention  
55 (Mahajan et al. 2021; Wiers et al. 2021). Acute alcohol intake increases the utilization of acetate, a  
56 metabolite of alcohol, at the expense of glucose utilization (Volkow et al. 2013; Volkow et al. 2017).  
57 In individuals with AUD, low brain glucose and high acetate metabolism persist beyond acute  
58 intoxication (Jiang et al. 2013; Tomasi et al. 2019; Volkow et al. 2017; Wang et al. 2013).  
59 Deprivation of acetate as an energy source during abstinence may contribute to alcohol withdrawal  
60 signs and symptoms, alcohol craving, and relapse in individuals with AUD (Mahajan et al. 2021).  
61 Ketone bodies [ $\beta$ -hydroxybutyrate (BHB)], acetoacetate, and acetone) resemble acetate and may  
62 provide an alternative to it as an energy source in the brain (Courchesne-Loyer et al. 2017). Previous  
63 work in our laboratory has demonstrated the efficacy of a high-fat, low-carbohydrate ketogenic  
64 dietary intervention in reducing alcohol withdrawal severity and alcohol craving in AUD patients  
65 undergoing alcohol detoxification (Wiers et al. 2021). These findings are concordant with preclinical  
66 models showing that a ketogenic diet reduces both the signs of alcohol withdrawal (Bornebusch et al.  
67 2021; Dencker et al. 2018; Tanabe et al. 2021) and alcohol self-administration (Blanco-Gandía et al.  
68 2021; Wiers et al. 2021).

69 Given the restrictive nature of the KD and poor patient adherence to the strict dietary regimen (Ye et  
70 al. 2015), exogenous BHB ketone supplementation provides an easier alternative to elevate plasma  
71 ketone bodies (Stubbs et al. 2017). Exogenous ketone supplementation is a well-tolerated  
72 intervention that may pose various health benefits: ketones improved cognition in preclinical and  
73 clinical models of Alzheimer's Disease (Kashiwaya et al. 2013; Newport et al. 2015; Pawlosky et al.  
74 2020); stabilized brain networks, thereby protecting the hypometabolic, aging brain (Mujica-Parodi  
75 et al. 2020); and decreased appetite in healthy human volunteers (Stubbs et al. 2018). Preclinical  
76 studies of AUD found that exogenous ketone ester (KE) decreases alcohol withdrawal signs, similar  
77 to a ketogenic diet (Bornebusch et al. 2021). However, the ability of exogenous KE to cross the blood  
78 brain barrier and alter brain energetics in AUD has not been demonstrated.

79 Here, we piloted the pharmacokinetic effects of a single dose of KE on brain energetics, measured  
80 with either positron emission tomography (PET) with  $^{18}\text{F}$ -Fluoro-deoxyglucose ( $^{18}\text{F}$ -FDG) or  
81 proton magnetic resonance spectroscopy ( $^1\text{H}$ -MRS) in individuals with AUD. All participants  
82 underwent two imaging sessions, once after KE intervention and once without KE (baseline). We  
83 chose the anterior cingulate cortex (dACC) as the main region of interest for  $^1\text{H}$ -MRS because  
84 previous studies have evidenced a role for the dACC in inhibitory control (Gan et al. 2014), alcohol  
85 craving (Bauer et al. 2013), and decision making (Acheson et al. 2009) and associated aberrations in  
86 the dACC with subsequent worsening of problems with alcohol (Cheetham et al. 2014; Zakiniaieiz et  
87 al. 2017). Furthermore, our previous research showed significant effects of a ketogenic diet on brain  
88 ketone and glutamate metabolism and functional reactivity to alcohol cues in the dACC (Li et al.  
89 2022; Wiers et al. 2021). We hypothesized that a single dose of KE would increase BHB levels in the  
90 brain and decrease the cerebral metabolic rate of glucose (CMR<sub>glc</sub>). For **Original Research**

91 **Articles, Clinical Trial Articles, and Technology Reports** the introduction should be succinct, with  
92 no subheadings. For **Case Reports** the Introduction should include symptoms at presentation,  
93 physical exams and lab results.

## 94 **2 Methods**

### 95 **2.1 Participants and ketone ester intervention**

96 Study participants were recruited for study protocol NCT04616781 or NCT05015881 via online  
97 advertisements (BuildClinical, iConnect) and underwent the following screening assessment: Mini  
98 International Neuropsychiatric Interview (MINI) for a DSM-5 diagnosis of AUD and other  
99 neuropsychiatric disorders (1), a 30-day Timeline Follow-back (TLFB) for daily drinking patterns (2),  
100 the Alcohol Use Disorders Identification Test (AUDIT) for hazardous drinking behavior (3), and the  
101 Shipley Institute of Living Scale-2 (Shipley-2) test for crystallized and fluid intelligence (4). Inclusion  
102 criteria included: 1) meeting DSM-5 criteria for current AUD; 2) self-report of an average of at least  
103 15 standard drinks per week in the last month; 3) self-report of having greater than a 1-yr history of  
104 heavy drinking; 4) having had a drink within 1 week of the study visit. Exclusion criteria included: 1)  
105 a current DSM-5 diagnosis of a major psychiatric disorder other than AUD; 2) intake of psychoactive  
106 medication within 24 hours of study participation; 3) history of seizures; 4) HIV seropositivity; 5) a  
107 history of head trauma with loss of consciousness for more than 30 min or associated skull  
108 fracture/abnormal MRI; 6) any contraindication for MRI (e.g., presence of ferromagnetic objects or  
109 claustrophobia), 7) a current, clinically significant physical disease or abnormality detected by medical  
110 history, physical examination, or routine laboratory evaluation that can impact brain function. A  
111 medical history and physical examination by a physician and routine laboratory results evaluated by a  
112 physician were conducted prior to study inclusion. Five AUD participants completed the MRI study (2  
113 females/ 3 males;  $45.2 \pm 17.0$  years old), and four AUD participants completed the  $^{18}\text{F}$ -FDG procedures  
114 (4 males;  $31 \pm 10$  years old) (**Table 1**). Two study participants were enrolled in both studies. The study  
115 protocols were approved by the University of Pennsylvania Institutional Review Board and all  
116 participants provided written informed consent before study participation.

117 Both study protocols used a cross-over design, in which a computer-generated randomization scheme  
118 assigned 50% of subjects to start with KE and 50% without KE on study visit 1, and the reverse on  
119 visit 2. On the active day, KE ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate KE solution, TdeltaS Global  
120 Inc.) was provided to participants at a dose of 395 mg/kg (2.2 mmol/kg) body weight.

121 Participants in the MRI study were asked to fast overnight and consumed a low-calorie breakfast  
122 approximately 2 hours before the scan. Participants were blinded to the study intervention and, during  
123 the baseline visit, received an isocaloric dextrose placebo (baseline) that was taste-matched using a  
124 bitterness additive (Symrise, US). The study drinks were prepared by the Penn Investigational Drug  
125 Service and provided to the participants 15 minutes prior to the MRI scan or approximately 45 minutes  
126 prior to the  $^1\text{H}$ -MRS scan.

127 Participants in the PET  $^{18}\text{F}$ -FDG study fasted for at least 6 hours prior to the study, as per standard  $^{18}\text{F}$ -  
128 FDG study protocols. Participants were aware of the study intervention. KE was diluted with diet soda  
129 or sparkling water by a trained staff member and administered to participants 1 hr prior to the PET  
130 scan. No intervention was provided on baseline (no KE) days.

### 131 **2.2 Blood measures of ketones and glucose**

132 Blood BHB and glucose levels were obtained from individuals participating in the PET  $^{18}\text{F}$ -FDG study.  
133 Blood BHB and glucose were measured at arrival, immediately prior to  $^{18}\text{F}$ -FDG injection, and 30 and  
134 60 min post injection. On KE days, these measures corresponded with the time prior to KE intake, and  
135 60 (immediately prior to scan), 90, and 120 min following KE intake. Measurements were made using  
136 a ketone and glucose meter (Abbott, Precision Xtra).

### 137 **2.3 Brain $^1\text{H}$ -MRS imaging and processing**

138 Participants underwent an MRI on a 3.0T Magnetom Prisma scanner (Siemens Medical Solutions USA  
139 Inc., Malvern, PA) equipped with a 64-channel head coil. Structural images were acquired using  $T_1$ -  
140 weighted magnetization prepared rapid-acquisition gradient-echo (MPRAGE) sequences with the  
141 following parameters: TR 2400 ms; TE 2.24 ms; TI 1060 ms; FOV 256 mm; 208 slices; slice thickness  
142 0.8 mm; flip angle  $9^\circ$ ; effective voxel resolution, 0.8 x 0.8 x 0.8 mm.

143 Localized proton magnetic resonance spectroscopy ( $^1\text{H}$ -MRS) was performed in a region of interest  
144 (ROI) located in the dACC (40x30x15mm), for which we previously demonstrated a sensitivity to  
145 ketones (5, 6). A semi-Laser (sLaser) spectral editing sequence for BHB was acquired, using an adapted  
146 sequence previously described (7). The parameters were as follows: TR 2000 ms; TE 72 ms; 256  
147 averages; Editing was performed with a gaussian pulse of 18.5 ms, amplitude of 47 Hz, and a bandwidth  
148 of 80 Hz at FWHM. For edit on, the pulse was centered at 4.14 ppm while for edit-off scans, it was  
149 centered at 5.26 ppm relative to a water position of 4.70 ppm. First- and second-order shimming was  
150 used to maximize the magnetic field  $B_0$  homogeneity in the voxel. Spectral fitting of the  $^1\text{H}$ -MRS  
151 datasets was carried with in-house written fitting software in IDL (NV5Geospatial, Broomfield, CO,  
152 USA) (8) with a modified basis set for the specific editing sequence and for ketone bodies (9). The  
153 basis set was simulated using GAMMA, part of the VESPA package (soher). The results from the  
154 analysis were inspected for nonrandom residuals and baseline fitting. Spectra with signal-to-noise ratio  
155 (SNR)  $< 15$  and linewidth  $> 0.1$  ppm were excluded from further analyses. A Cramér–Rao lower bound  
156 (CRLBs) of 20% for each individual peak was used as a quality criterion (8). To place the voxel in the  
157 same dACC ROI during the second scan, the program ImScribe  
158 (<https://www.med.upenn.edu/CAMIPM/imscribe.html>) was used, which is designed to allow  
159 reproducible selection of the same anatomical ROI in Siemens MRI studies within the same subject  
160 over multiple MRI scans. ImScribe uses high-resolution  $T_1$ -weighted images and the spectroscopy  
161 voxel information from the first scan as target template and  $T_1$ -weighted images of the subsequent scan  
162 and perform affine coregistration that provides the information of the new spectroscopic voxel  
163 placement for the later scans (10, 11). This was completed (~2 minutes) and this ROI was transferred  
164 to the Siemen’s console as a DICOM image and used to prescribe the  $^1\text{H}$ -MRS acquisition.

### 165 **2.4 $^{18}\text{F}$ -FDG PET scanning and processing**

166 On two separate study days participants underwent a 60-min  $^{18}\text{F}$ -FDG PET/CT scan using the PennPET  
167 Explorer (12), a 140 cm axial field of view whole-body PET scanner. Venous catheters were placed in  
168 the antecubital vein bilaterally for radiotracer injection and blood sampling. Commercially  
169 manufactured  $^{18}\text{F}$ -FDG (~10 mCi) was injected intravenously over a period of approximately 1 min.  
170 During the PET imaging procedures, the subjects rested quietly under dim illumination and minimal  
171 acoustic noise. To ensure that subjects did not fall asleep, they were monitored throughout the  
172 procedure and were asked to keep their eyes open.

173 Dynamic PET images were reconstructed into 4-mm voxels using time-of-flight list-mode ordered-  
174 subsets expectation maximization into 39 frames: 12 x 5 s, 6 x 10 s, 3 x 20 s, 2 x 30 s, 6 x 60 s, and 10

175 x 300 s. Images were corrected for interframe motion and analyzed in PMOD v3.7 (PMOD  
176 Technologies, Zurich, Switzerland). Whole brain and voxel-wise flux (K) were computed using Patlak  
177 graphical modeling (13) and an image-derived aortic arch blood pool  $SUV_{peak}$  input function with a  
178 plasma:whole blood ratio of 1:1. Measured  $^{18}F$ -FDG flux was converted to glucose metabolism using  
179 the formula  $MR_{Glc} = K * PG / LC$ , where PG is the averaged plasma glucose levels from pre-injection,  
180 30-min, and 60-min post-injection samples, and LC is a lumped constant of 0.8 (14). The cerebral  
181 metabolic rate for glucose consumption (CMR<sub>Glc</sub>) maps in  $\mu\text{mol}/100 \text{ mL}/\text{min}$  were aligned to the  
182 subject's structural MRI and then normalized to the MNI template with a 2-mm isotropic resolution  
183 using the FSL Software Library (version 5.0; <http://www.fmrib.ox.ac.uk/fsl>)(15).

## 184 2.5 Statistical analyses

185 All statistical analyses were conducted using SPSS (IBM, Armonk, NY). We performed linear mixed-  
186 effects analysis to examine the effects of the intervention (KE vs. baseline), time (assessment time  
187 points), and time x intervention interaction on blood measures of BHB and glucose. The models also  
188 controlled for visit order (KE at the first or second visit) and included subject-specific random  
189 intercepts. *Post hoc* pairwise comparisons were performed with Bonferroni correction. Paired t-tests  
190 were used to compare cingulate BHB and whole-brain CMR<sub>Glc</sub> between KE and baseline study  
191 conditions. Exploratory voxel-wise FDG comparisons between KE vs baseline were performed using  
192 a paired t-test in SPM12 (<http://www.fil.ion.ucl.ac.uk/spm/>) with a cluster-defining threshold of  
193 uncorrected  $p < 0.0001$  and cluster size  $k > 50$ , and cluster-level threshold of familywise error (FEW)-  
194 corrected  $p < 0.05$ .

## 195 3 Results

### 196 3.1 Blood levels of ketones and glucose

197 BHB levels were significantly higher following KE than baseline (Intervention:  $F_{1,19.3}=236$ ,  $p < 0.001$ ;  
198 Intervention x time:  $F_{3,19.3}=36$ ,  $p < 0.001$ ) and they changed with time ( $F_{1,19.3}=39$ ,  $p < 0.001$ ). *Post hoc*  
199 analysis showed significant differences in BHB levels between baseline and KE at 60-, 90-, and 120-  
200 min post-KE administration. KE increased blood BHB levels approximately 27 fold from a pre-KE  
201 level of  $0.15 \text{ mM} \pm 0.12 \text{ SD}$  to  $4.06 \text{ mM} \pm 0.42 \text{ SD}$  120 min following administration (**Figure 1A**).  
202 Blood glucose levels were lower during the KE intervention than baseline (Intervention:  $F_{1,19}=31$ ,  
203  $p < 0.001$ ) and changed with time ( $F_{1,19}=12$ ,  $p < 0.001$ ), but no time x intervention interaction effects  
204 were observed ( $F_{3,19.0}=1$ ,  $p=0.4$ ) (**Figure 1B**). *Post hoc* analysis showed lower blood glucose levels  
205 between the intervention arms prior to KE administration.

### 206 2.2 Brain BHB and CMR<sub>Glc</sub>

207 BHB levels in the dACC were significantly higher 45 min after KE intake (mean= $0.83 \pm 0.13 \text{ mM}$ )  
208 than baseline visit (mean= $0.28 \pm 0.11 \text{ mM}$ ) ( $t_4=13.4$ ,  $p < 0.001$ ), as measured with  $^1\text{H}$ -MRS in 5 AUD  
209 participants (**Figure 2A**).

210 Whole-brain CMR<sub>Glc</sub> decreased by 17% with KE (mean CMR<sub>Glc</sub> =  $14.4 \mu\text{mol}/100\text{g}/\text{min} \pm 1.5 \text{ SD}$ ) vs.  
211 baseline (mean =  $17.4 \pm 2.3 \mu\text{mol}/100\text{g}/\text{min}$ ) ( $t_3=5.7$ ,  $p=0.01$ ) in 4 AUD participants (**Figure 2B**).

212 An exploratory voxel-wise analysis indicated that the largest KE-induced CMR<sub>Glc</sub> reductions were in  
213 the frontal cortex, including the bilateral inferior frontal gyrus (IFG), occipital cortex, parietal and

214 temporal lobe, anterior cingulate cortex, bilateral amygdalae, hippocampi and insulae (all  $p_{FWE} < 0.05$ )  
215 (Figure 2B, Table 2).

## 216 4 Discussion

217 We found that a single dose of the KE (*R*)-3-hydroxybutyl (*R*)-3-hydroxybutyrate (TdeltaS Global Inc.)  
218 rapidly elevated blood ketone levels and shifted brain energetics from glucose to ketones in individuals  
219 with AUD. While blood BHB remained low (~0.2 mM) through the baseline visit, it increased to 3.2  
220 mM within 1 hr of KE administration and to 4.1 mM after 2 hr. Quantification of brain BHB levels and  
221 glucose utilization with <sup>1</sup>H-MRS and PET, respectively, showed higher dACC BHB levels and lower  
222 whole-brain glucose metabolism following KE administration compared to baseline in individuals with  
223 AUD.

224 Glucose is the primary fuel for the brain and is necessary for normal neural functioning, including  
225 maintaining a resting potential, generating an action potential, and synthesizing neurotransmitters and  
226 neuromodulators (16, 17). Ketone bodies are produced endogenously in the liver during periods in  
227 which glucose is not readily available, such as when an individual is adherent to a high-fat, low-  
228 carbohydrate ketogenic diet. They are carried through the bloodstream and transported into neurons by  
229 monocarboxylate transporters, where they are utilized for fuel (18). Exogenous KE supplements  
230 provide a faster, less dietary restrictive alternative to a ketogenic diet to achieve nutritional ketosis (19-  
231 21). As demonstrated in our study, within 1-2 hr of administration KE elevated blood BHB levels  
232 similar to those seen following 1-2 wk of adherence to a ketogenic diet (5). Similar blood BHB levels  
233 have previously been reported with the same dose of KE (19). Localized <sup>1</sup>H-MRS provides a non-  
234 invasive method to measure ketone levels in the brains of individuals adhering to a ketogenic diet (9,  
235 22). We found rapid and efficient brain uptake of BHB following KE administration and demonstrated  
236 significantly higher BHB levels in the dACC during the KE session than the baseline session.  
237 Furthermore, KE yielded lower blood glucose levels, which may be due to a small KE-induced increase  
238 in insulin levels (19, 23). Moreover, we found an average 17% reduction in CMR<sub>glc</sub> from baseline to  
239 KE, which is comparable to that previously observed following 4 days of a ketogenic diet intervention  
240 (24). It is important to note that reductions in CMR<sub>glc</sub> have been found to be proportionate to plasma  
241 BHB levels (25), and not to hypoglycemia *per se* (24). In contrast, plasma levels of glucose correlate  
242 inversely with brain glucose metabolism and hyperglycemia has been associated with significantly  
243 lower brain glucose metabolism (26). Thus, our findings are in line with previous reports that CMR<sub>glc</sub>  
244 is inversely associated with blood and brain ketone levels (24), and thus that when plasma ketones  
245 increase, the human brain meets its metabolic needs by reducing CMR<sub>glc</sub> in relation to ketone  
246 availability and uptake.

247 Emerging evidence attributes heavy alcohol consumption and AUD to deficiencies in brain energy  
248 metabolism (18, 27). Acetate is a byproduct of alcohol metabolism and produces energy through  
249 conversion to acetyl-coenzyme A and metabolism in the tricarboxylic acid (TCA) cycle (28). Alcohol  
250 intoxication acutely increases plasma levels of acetate, brain uptake of acetate, and decreases brain  
251 glucose utilization (27, 29). Chronic use of alcohol produces metabolic adaptations that exacerbate this  
252 shift in brain energetics and increase the brain's reliance on acetate for energy (27, 30). Similarly, gene  
253 and protein analysis from rodents and post-mortem human brain tissues show a reduction in glucose  
254 metabolism pathways (i.e., glycolysis and gluconeogenesis) and increased expression of  
255 monocarboxylated transporters after chronic alcohol use (31, 32). It has been hypothesized that  
256 deprivation of acetate as an energy source and inability to abruptly transition to utilizing glucose during  
257 abstinence contribute to alcohol withdrawal signs and symptoms and alcohol craving in individuals  
258 undergoing detoxification (18, 27). Heavy drinkers also demonstrated higher levels of <sup>13</sup>C-labeled brain  
259 acetate than light drinkers (33). Ketone bodies are similar to acetate in that they also are converted to

260 acetyl-coenzyme A and produce energy in the TCA cycle. Targeting brain energetics with a ketogenic  
261 dietary intervention was previously shown to increase blood and brain ketone levels and attenuate  
262 withdrawal signs and symptoms and alcohol craving in individuals with AUD who were undergoing  
263 alcohol detoxification treatment (5). Here we demonstrated that KE rapidly increases blood and brain  
264 BHB levels and reduces the need for brain glucose utilization in individuals with AUD, and may thus  
265 serve as a more palatable alternative to a ketogenic dietary intervention in treating individuals with  
266 AUD.

267 Our study has several limitations and identifies potential areas for future study. First, although we  
268 employed a cross-over design to mitigate potential confounding effects of inter-individual differences,  
269 the study sample is small. Second, our sample was limited to individuals with AUD. It has been well  
270 demonstrated that individuals with AUD have lower brain glucose metabolism than non-dependent  
271 healthy controls (27, 34, 35). Moreover, alcohol-induced increases in acetate metabolism correlate with  
272 alcohol drinking history and were greater in heavy drinkers than social drinkers, suggesting that heavy  
273 or chronic alcohol exposure facilitates the use of acetate as a brain energy substrate (30). Thus, future  
274 studies are needed to compare KE-induced increases in BHB levels and reductions in CMR<sub>glc</sub> between  
275 individuals with AUD and non-dependent volunteers, to ascertain whether KE-induced elevations in  
276 ketones and reductions in CMR<sub>glc</sub> are greater among individuals who are very heavy alcohol  
277 consumers. Third, <sup>1</sup>H-MRS cannot differentiate between intracellular and extracellular levels of BHB  
278 and is thus limited in assessing BHB utilization in the brain. Fourth, *post hoc* pairwise analysis showed  
279 lower blood glucose in the KE treatment arm compared to the baseline visit prior to KE administration,  
280 which may have been confounding. However, all CMR<sub>glc</sub> analyses were corrected for blood glucose  
281 level, and likely did not affect the strong KE-induced reductions in CMR<sub>glc</sub>. Indeed, previous studies  
282 reported an inverse relationship between blood and brain glucose, such that higher brain glucose uptake  
283 was seen in individuals with lower blood glucose levels (26, 36, 37). Therefore, our findings of  
284 decreased brain glucose uptake with KE *despite* lower blood glucose levels supports the robust effect  
285 of KE in altering brain energetics. Last, the implications of KE-induced changes in brain energetics on  
286 clinical outcomes in AUD are unknown. To address this gap in the literature, we plan to conduct studies  
287 that examine the effects of KE on alcohol withdrawal and alcohol craving in individuals with AUD.

288 In sum, our findings provide the first evidence that KE administration rapidly shifts brain energetics  
289 from glucose to ketone metabolism in individuals with AUD. Understanding the neurometabolic  
290 effects of KE may provide a scientific basis for studies examining the feasibility of utilizing KE as a  
291 treatment option for AUD or other neuropsychiatric and neurological disorders. Such findings may  
292 also help to identify potential neural mechanisms for these clinical effects.

## 293 **5 Author Contributions**

294 CEW designed the study. XL, JB, SV, RR, TP, ME, RR, HK, RPRN, JGD collected the data. AY,  
295 LSP, RKD, RR, RPRN, JVDV, CEW, and ZS analyzed the data and interpreted the results. XL, ZS,  
296 HK, AY, RPRN, and CEW wrote the manuscript. All authors provided critical revision of the  
297 manuscript for intellectual content and approved the final version of the manuscript.

## 298 **6 Funding**

299 This work was supported by the Institute for Translational Medicine and Therapeutics' (ITMAT)  
300 Transdisciplinary Program in Translational Medicine and Therapeutics (Wiers & Dubroff), a  
301 NARSAD Young Investigator Grant (28778, Wiers), and the following National Institutes of Health  
302 grants: AA026892 (Wiers), DA051709 (Shi), DA046345 (Kranzler), and and P41 EB029460 (Reddy).  
303 Dr. Li was supported by T32DA028874.



## 304 **7 Acknowledgments**

305 We thank Laurie Downing, Kim Olson, Klaudia Glogowska, Rachel Weyl, Erin Schubert, Matt Furey,  
306 Regan Scheffer, Kayla Spooner, Reagan Wetherill, Nora Volkow, Paco Bravo, Aiden Adams, David  
307 Mankoff, Robert Mach, and the Penn PET Center for their contributions.

## 308 **8 Conflict of Interest**

309 *The authors declare that the research was conducted in the absence of any commercial or financial*  
310 *relationships that could be construed as a potential conflict of interest.*

## 311 **9 Data Availability Statement**

312 The data that support the findings of this study are available from the corresponding author upon  
313 reasonable request.

## 314 **10 References**

- 315 1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-  
316 International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured  
317 diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59 Suppl 20:22-  
318 33;quiz 4-57.
- 319 2. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported alcohol  
320 consumption. *Measuring alcohol consumption: Psychosocial and biochemical methods*. Totowa, NJ,  
321 US: Humana Press/Springer Nature; 1992. p. 41-72.
- 322 3. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol  
323 Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of  
324 Persons with Harmful Alcohol Consumption--II. *Addiction*. 1993;88(6):791-804.
- 325 4. Zachary RA, Paulson MJ, Gorsuch RL. Estimating WAIS IQ from the Shipley Institute of  
326 Living Scale using continuously adjusted age norms. *J Clin Psychol*. 1985;41(6):820-31.
- 327 5. Wiers CE, Vendruscolo LF, van der Veen J-W, Manza P, Shokri-Kojori E, Kroll DS, et al.  
328 Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents.  
329 *Science Advances*. 2021;7(15):eabf6780.
- 330 6. Li X, Shi Z, Byanyima J, Morgan PT, van der Veen JW, Zhang R, et al. Brain glutamate and  
331 sleep efficiency associations following a ketogenic diet intervention in individuals with Alcohol Use  
332 Disorder. *Drug Alcohol Depend Rep*. 2022;5.
- 333 7. Landheer K, Gajdošík M, Juchem C. A semi-LASER, single-voxel spectroscopic sequence  
334 with a minimal echo time of 20.1 ms in the human brain at 3 T. *NMR Biomed*. 2020;33(9):e4324.
- 335 8. van der Veen JW, Marengo S, Berman KF, Shen J. Retrospective correction of frequency drift  
336 in spectral editing: The GABA editing example. *NMR Biomed*. 2017;30(8).
- 337 9. Cecil KM, Mulkey SB, Ou X, Glasier CM. Brain ketones detected by proton magnetic  
338 resonance spectroscopy in an infant with Ohtahara syndrome treated with ketogenic diet. *Pediatr*  
339 *Radiol*. 2015;45(1):133-7.
- 340 10. Wolf DH, Satterthwaite TD, Loughhead J, Pinkham A, Overton E, Elliott MA, et al. Amygdala  
341 abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine  
342 challenge. *Psychopharmacology (Berl)*. 2011;218(3):503-12.
- 343 11. Nanga RP, Hariharan H, Reddy R. Fully automated macromolecule suppressed single voxel  
344 glutamate spectroscopy (FAMOUS SVGS). *J Transl Med*. 2016;14(1):220.

- 345 12. Dai B, Daube-Witherspoon ME, McDonald S, Werner ME, Parma MJ, Geagan MJ, et al.  
346 Performance evaluation of the PennPET explorer with expanded axial coverage. *Phys Med Biol*.  
347 2023;68(9).
- 348 13. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer  
349 constants from multiple-time uptake data. *J Cereb Blood Flow Metab*. 1983;3(1):1-7.
- 350 14. Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, et al. A cross-sectional  
351 comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild  
352 cognitive impairment and early Alzheimer's disease. *Exp Gerontol*. 2018;107:18-26.
- 353 15. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al.  
354 Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage*.  
355 2004;23 Suppl 1:S208-19.
- 356 16. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. *J*  
357 *Cereb Blood Flow Metab*. 2001;21(10):1133-45.
- 358 17. Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in  
359 physiological and pathological brain function. *Trends Neurosci*. 2013;36(10):587-97.
- 360 18. Mahajan VR, Elvig SK, Vendruscolo LF, Koob GF, Darcey VL, King MT, et al. Nutritional  
361 Ketosis as a Potential Treatment for Alcohol Use Disorder. *Front Psychiatry*. 2021;12:781668.
- 362 19. Stubbs BJ, Cox PJ, Evans RD, Cyranka M, Clarke K, de Wet H. A Ketone Ester Drink  
363 Lowers Human Ghrelin and Appetite. *Obesity*. 2018;26(2):269-73.
- 364 20. Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, et al. On the Metabolism of  
365 Exogenous Ketones in Humans. *Front Physiol*. 2017;8:848.
- 366 21. Mujica-Parodi LR, Amgalan A, Sultan SF, Antal B, Sun X, Skiena S, et al. Diet modulates  
367 brain network stability, a biomarker for brain aging, in young adults. *Proceedings of the National*  
368 *Academy of Sciences of the United States of America*. 2020;117(11):6170-7.
- 369 22. Wright JN, Saneto RP, Friedman SD.  $\beta$ -Hydroxybutyrate Detection with Proton MR  
370 Spectroscopy in Children with Drug-Resistant Epilepsy on the Ketogenic Diet. *AJNR Am J*  
371 *Neuroradiol*. 2018;39(7):1336-40.
- 372 23. Veech RL, Bradshaw PC, Clarke K, Curtis W, Pawlosky R, King MT. Ketone bodies mimic  
373 the life span extending properties of caloric restriction. *IUBMB Life*. 2017;69(5):305-14.
- 374 24. Courchesne-Loyer A, Croteau E, Castellano CA, St-Pierre V, Hennebelle M, Cunnane SC.  
375 Inverse relationship between brain glucose and ketone metabolism in adults during short-term  
376 moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. *J Cereb*  
377 *Blood Flow Metab*. 2017;37(7):2485-93.
- 378 25. Hasselbalch SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, et al. Changes in  
379 cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. *The American*  
380 *journal of physiology*. 1996;270(5 Pt 1):E746-51.
- 381 26. Sarikaya I, Albatineh AN, Sarikayaa A. Effect of various blood glucose levels on regional  
382 FDG uptake in the brain. *Asia Ocean J Nucl Med Biol*. 2020;8(1):46-53.
- 383 27. Volkow ND, Wiers CE, Shokri-Kojori E, Tomasi D, Wang GJ, Baler R. Neurochemical and  
384 metabolic effects of acute and chronic alcohol in the human brain: Studies with positron emission  
385 tomography. *Neuropharmacology*. 2017;122:175-88.
- 386 28. Bose S, Ramesh V, Locasale JW. Acetate Metabolism in Physiology, Cancer, and Beyond.  
387 *Trends Cell Biol*. 2019;29(9):695-703.
- 388 29. Volkow ND, Wang GJ, Franceschi D, Fowler JS, Thanos PP, Maynard L, et al. Low doses of  
389 alcohol substantially decrease glucose metabolism in the human brain. *Neuroimage*. 2006;29(1):295-  
390 301.
- 391 30. Volkow ND, Kim SW, Wang G-J, Alexoff D, Logan J, Muench L, et al. Acute alcohol  
392 intoxication decreases glucose metabolism but increases acetate uptake in the human brain.  
393 *NeuroImage*. 2013;64:277-83.

- 394 31. Bhat UA, Kumar SA, Chakravarty S, Patel AB, Kumar A. Differential Effects of Chronic  
 395 Ethanol Use on Mouse Neuronal and Astroglial Metabolic Activity. *Neurochemical Research*.  
 396 2023;48(8):2580-94.
- 397 32. Enculescu C, Kerr ED, Yeo KYB, Schenk G, Fortes MRS, Schulz BL. Proteomics Reveals  
 398 Profound Metabolic Changes in the Alcohol Use Disorder Brain. *ACS Chem Neurosci*.  
 399 2019;10(5):2364-73.
- 400 33. Jiang L, Gulanski BI, De Feyter HM, Weinzimer SA, Pittman B, Guidone E, et al. Increased  
 401 brain uptake and oxidation of acetate in heavy drinkers. *J Clin Invest*. 2013;123(4):1605-14.
- 402 34. Tomasi DG, Wiers CE, Shokri-Kojori E, Zehra A, Ramirez V, Freeman C, et al. Association  
 403 Between Reduced Brain Glucose Metabolism and Cortical Thickness in Alcoholics: Evidence of  
 404 Neurotoxicity. *The international journal of neuropsychopharmacology / official scientific journal of*  
 405 *the Collegium Internationale Neuropsychopharmacologicum*. 2019;22(9):548-59.
- 406 35. Wiers CE, Cabrera E, Skarda E, Volkow ND, Wang GJ. PET imaging for addiction medicine:  
 407 From neural mechanisms to clinical considerations. *Progress in brain research*. 2016;224:175-201.
- 408 36. Sprinz C, Zanon M, Altmayer S, Watte G, Irion K, Marchiori E, et al. Effects of blood  
 409 glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an  
 410 analysis on 5623 patients. *Sci Rep*. 2018;8(1):2126.
- 411 37. Sarikaya I, Sarikaya A, Sharma P. Assessing the Effect of Various Blood Glucose Levels on  
 412 (18)F-FDG Activity in the Brain, Liver, and Blood Pool. *J Nucl Med Technol*. 2019;47(4):313-8.

413

## 414 11 Figure legends

415 **Figure 1. Blood ketone and glucose levels with Ketone Ester (KE).** (A) Blood ketone (BHB) levels  
 416 increased 27x with KE (mean baseline = 0.15 mM ± 0.12, KS=4.06 mM ± 0.42, Intervention x Time:  
 417  $F_{3,6}=31.37$ ,  $p<0.001$ ). (B) There was no Intervention x Time effect for glucose levels, but significant  
 418 main effects of Intervention ( $F_{1,19}=31$ ,  $p<0.001$ ) and Time ( $F_{1,19}=12$ ,  $p<0.001$ ).

419

420 **Figure 2. Brain pharmacokinetics of Ketone Ester (KE).** (A) Beta-hydroxybutyrate (BHB) levels  
 421 in the anterior cingulate cortex were significantly higher 45 min after KE intake (mean=0.83±0.13)  
 422 than at the baseline visit (mean=0.28±0.11) as measured with <sup>1</sup>H-MRS in 5 AUD participants. (B)  
 423 Whole-brain metabolic rate of glucose (CMRglc) decreased significantly with KE (mean CMRglc=  
 424 14.4±1.5 μmol/100g/min) vs. baseline (mean=17.4±2.3 μmol/100g/min) in 4 AUD participants.  
 425 Average whole-brain CMRglc shows the strongest effects of KE in lowering brain glucose metabolism  
 426 in the frontal cortex, occipital cortex, temporal cortex, and anterior cingulate (all  $p < 0.05$ ). \* $p < 0.05$   
 427 \*\*\* $p < 0.001$ .

428

## 429 12 Tables

430

**Table 1.** Demographics and clinical characteristics of the participants in the <sup>1</sup>H-MRS and <sup>18</sup>F-FDG PET studies. Data are presented as mean ± SD

Characteristic	MRI study (n=5)	FDG study (n=4)
Sex at birth	2 females/ 3 males	4 males
Age (years)	45.2 ±17.0	31 ± 10
Race	3 African American/ 2 Caucasian	2 African American/ 2 Caucasian

BMI (kg/m <sup>2</sup> )	26.3 ± 5.3	30.6 ± 2.7
Shipley IQ score	106.6 ± 7.2	106.5 ± 20.0
Drinks/week	28.3 ± 10.1	27.2 ± 3.0
AUDIT	17.4 ± 6.8	15.0 ± 4.8

Abbreviation: AUDIT, Alcohol Use Disorders Identification Test; BMI, Body-Mass Index

431  
432  
433

**Table 2.** Brain regions showing a significant main effect of Intervention.

Brain Region	Cluster size (mm <sup>3</sup> )	Z	MNI coordinates
<b><i>KE &lt; Baseline</i></b>			
Frontal cortex, IFG, Precentral gyrus	199	5.32	62, 2, 36
Frontal cortex, IFG, Precentral gyrus, Insula	8449	5.18	-46, -12, 28
Precuneus, Parietal lobe	524	4.98	-24, -60, 42
Occipital cortex, Fusiform gyrus, Temporal lobe	4019	4.93	60, -70, 24
Anterior Cingulate, dACC, Posterior Cingulate	1300	4.53	-8, 14, 26
Insula	207	4.22	40, 0, 16
Brainstem, Pons	798	4.21	10, -16, -34
Amygdala, Hippocampus	332	4.19	-24, -4, -24
Superior frontal gyrus	174??	4.18	-14, 22, 58
Amygdala, Hippocampus	193	3.86	38, 0, -20
Precentral, Middle frontal gyrus	238	3.81	38, -12, 60
Precuneus, Parietal lobe	399	3.79	30, -56, 48

***Baseline < KE***

*No significant clusters*

**Abbreviations:** dACC, dorsal Anterior Cingulate Cortex, IFG Inferior Frontal Gyrus, MNI, Montreal Neurological Institute

434  
435